Sequential Anti-Cytomegalovirus Response Monitoring May Allow Prediction of Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Borchers, Sylvia ^a   Bremm, Melanie ^b   Lehrnbecher, Thomas ^b   Dammann, Elke ^a   Pabst, Brigitte ^a   Wölk, Benno ^a   Esser, Ruth ^b   Yildiz, Meral ^b   Eder, Matthias ^a   Stadler, Michael ^a   Bader, Peter ^b   Martin, Hans ^b   Jarisch, Andrea ^b   Schneider, Gisbert ^c   Klingebiel, Thomas ^b   Ganser, Arnold ^a   Weissinger, Eva M ^a   Koehl, Ulrike ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN; HLA B ANTIGEN; TETRAMER;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTICYTOMEGALOVIRUS RESPONSE MONITORING; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD ANALYSIS; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRESCHOOL CHILD; SCHOOL CHILD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; KINETICS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; TRANSPLANTATION, HOMOLOGOUS;

CYTOMEGALOVIRUS;

EID: 84871277195     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050248     Document Type: Article

References (41)

1. Mori T, Kato J, (2010) Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol 91: 588-595.
2. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, et al. (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 9: 543-558.
3. Hebart H, Einsele H, (2004) Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 65: 432-436.
4. Torres HA, Aguilera E, Safdar A, Rohatgi N, Raad II, et al. (2008) Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. Clin Microbiol Infect 14: 1160-1166.
5. Ljungman P, Griffiths P, Paya C, (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34: 1094-1097.
6. Olkinuora HA, Taskinen MH, Saarinen-Pihkala UM, Vettenranta KK, (2010) Multiple viral infections post-hematopoietic stem cell transplantation are linked to the appearance of chronic GVHD among pediatric recipients of allogeneic grafts. Pediatr Transplant 14: 242-248.
7. Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, et al. (2010) Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant [Epub ahead of print].
8. van Burik JA, Carter SL, Freifeld AG, High KP, Godder KT, et al. (2007) Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 13: 1487-1498.
9. Lilleri D, Gerna G, Fornara C, Chiesa A, Comolli G, et al. (2009) Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-depleted, allogeneic hematopoietic stem cell transplantation. J Infect Dis 199: 829-836.
10. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, et al. (2006) Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91: 78-83.
11. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA, (1997) Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 64: 108-113.
12. Battiwalla M, Wu Y, Bajwa RP, Radovic M, Almyroudis NG, et al. (2007) Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 13: 765-770.
13. Borchers S, Luther S, Lips U, Hahn N, Kontsendorn J, et al. (2011) Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 13: 222-236.
14. Brooimans RA, Boyce CS, Popma J, Broyles DA, Gratama JW, et al. (2008) Analytical performance of a standardized single-platform MHC tetramer assay for the identification and enumeration of CMV-specific CD8+ T lymphocytes. Cytometry A 73: 992-1000.
15. Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, et al. (2010) Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 116: 1655-1662.
16. Gratama JW, van Esser JW, Lamers CH, Tournay C, Lowenberg B, et al. (2001) Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98: 1358-1364.
17. Heijnen IA, Barnett D, Arroz MJ, Barry SM, Bonneville M, et al. (2004) Enumeration of antigen-specific CD8+ T lymphocytes by single-platform, HLA tetramer-based flow cytometry: a European multicenter evaluation. Cytometry B Clin Cytom 62: 1-13.
18. Koehl U, Dirkwinkel E, Koenig M, Erben S, Soerensen J, et al. (2008) Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group. Klin Padiatr 220: 348-352.
19. Giest S, Grace S, Senegaglia AC, Pasquini R, Gonzalo-Daganzo RM, et al. (2010) Cytomegalovirus-specific CD8+T cells targeting different HLA/peptide combinations correlate with protection but at different threshold frequencies. British Journal of Haematology 148: 311-322.
20. Koehl U, Bochennek K, Esser R, Brinkmann A, Quaritsch R, et al. (2008) ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56+CD3- NK cells. Int J Hematol 87: 98-105.
21. Koenig M, Huenecke S, Salzmann-Manrique E, Esser R, Quaritsch R, et al. (2010) Multivariate analyses of immune reconstitution in children after allo-SCT: risk-estimation based on age-matched leukocyte sub-populations. Bone Marrow Transplant 45: 613-621.
22. Verboom M, Hallensleben M, Horn PA, Blasczyk R, (2007) Bioinformatic integration of biomechanics makes HLA sequencing universally applicable. Tissue Antigens 70: 338-339.
23. Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, et al. (2010) Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood 115: 4111-4119.
24. Yao J, Bechter C, Wiesneth M, Harter G, Gotz M, et al. (2008) Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis 46: e96-105.
25. Chen FE, Aubert G, Travers P, Dodi IA, Madrigal JA, (2002) HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. Cytotherapy 4: 41-48.
26. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, et al. (2001) Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97: 1232-1240.
27. Morita Y, Hosokawa M, Ebisawa M, Sugita T, Miura O, et al. (2005) Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 36: 803-811.
28. Akiyama Y, Kuzushima K, Tsurumi T, Yamaguchi K, (2004) Analysis of HLA-A24-restricted CMVpp65 peptide-specific CTL with HLA-A*2402-CMVpp65 tetramer. Immunol Lett 95: 199-205.
29. Akiyama Y, Maruyama K, Mochizuki T, Sasaki K, Takaue Y, et al. (2002) Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. Immunol Lett 83: 21-30.
30. Gondo H, Himeji D, Kamezaki K, Numata A, Tanimoto T, et al. (2004) Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation. Int J Hematol 80: 441-448.
31. Masuoka M, Yoshimuta T, Hamada M, Okamoto M, Fumimori T, et al. (2001) Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. Viral Immunol 14: 369-377.
32. Provenzano M, Mocellin S, Bettinotti M, Preuss J, Monsurro V, et al. (2002) Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells. J Immunother 25: 342-351.
33. Lacey SF, Villacres MC, La Rosa C, Wang Z, Longmate J, et al. (2003) Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 64: 440-452.
34. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, et al. (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201: 1031-1036.
35. Khan N, Best D, Bruton R, Nayak L, Rickinson AB, et al. (2007) T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. Journal of Immunology 178: 4455-4465.
36. Sacre K, Nguyen S, Deback C, Carcelain G, Vernant JP, et al. (2008) Expansion of Human Cytomegalovirus (HCMV) Immediate-Early 1-Specific CD8(+) T Cells and Control of HCMV Replication after Allogeneic Stem Cell Transplantation. Journal of Virology 82: 10143-10152.
37. Simon CO, Holtappels R, Tervo HM, Bohm V, Daubner T, et al. (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80: 10436-10456.
38. Tormo N, Solano C, Benet I, Nieto J, de la Camara R, et al. (2010) Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. J Med Virol 82: 1208-1215.
39. Lilleri D, Zelini P, Fornara C, Comolli G, Revello MG, et al. (2009) Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host. Clin Immunol 131: 395-403.
40. Tormo N, Solano C, Benet I, Clari MA, Nieto J, et al. (2010) Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 45: 543-549.
41. Gallez-Hawkins G, Thao L, Lacey SF, Martinez J, Li X, et al. (2005) Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 11: 890-902.